NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Coronavirus
Deadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Deadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Press Release: ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study...
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage...
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief...
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"),...
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a...
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment...
DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025...
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company,...
NanoViricides Presenting at NIBA’s 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 – Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing...
Eltek Ltd. Reports Full Year and Fourth Quarter 2026 Financial Results
PETACH TIKVA, Israel, March 9, 2026 /PRNewswire/ -- Eltek Ltd. (NASDAQ: ELTK), a global manufacturer and supplier of technologically advanced...
First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine...
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology...
QScreen AI Announces Strategic Financing to Advance Commercialization Initiatives Across North America
Toronto, Ontario--(Newsfile Corp. - February 26, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator...
QScreen AI Advances Structured Commercial Discussions Following Canadian Trade Mission to Mexico
Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator...
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
– Administration of PEDMARK® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for...
QScreen AI Advances Quantum-Inspired Optimization with U.S. Patent Filing; Gains National Spotlight on CBC
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator...